Trial Profile
A Phase II trial of HORA-RPE65
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs HORA-RPE65 (Primary)
- Indications Leber congenital amaurosis
- Focus Therapeutic Use
- Sponsors Coave Therapeutics
- 26 Sep 2017 New trial record